Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. (NASDAQ:RLAY) is the next best biotech stock on our list. TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target. The firm said the upcoming VIKTORIA-1 trial readout for Celcuity’s gedatolisib could act as a positive catalyst for mutant-selective inhibitors such as RLAY’s zovegalisib. Oppenheimer expects the VIKTORIA-1 results to fall short of ...